AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.
AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday. AbbVie and co-developer Pfizer's drug, Emblaveo, is approved in ...
AbbVie (NYSE:ABBV) said it has received FDA approval for its intravenous antibiotic treatment Emblaveo. The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results